I agree that there is little use to copy abstracts of in vitro testing. But interesting info can sometimes be identified even that early in the research process, and the Chinese scientists and their peers thought that it was important enough to have it published in a scientific journal. And some of you were kind of excited.
Being honest as I am, I must tell you that I disagree with your claim of the Chinese research being 10 -15 years behind PBT2. Honestly, I don't think that in my opinion either of the two MOA's will gain much headway toward eventual approval for commercialization. Time will tell - possibly in 10 to 15 years.
- Forums
- ASX - By Stock
- ATH
- Orphan designation benefits ?
Orphan designation benefits ?, page-21
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $9.838K | 3.277M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
75 | 100044686 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 157644647 | 64 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
75 | 100044686 | 0.002 |
26 | 140640147 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 156344647 | 62 |
0.005 | 8366584 | 12 |
0.006 | 16581534 | 13 |
0.007 | 52264874 | 24 |
0.008 | 37620994 | 28 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online